https://www.selleckchem.com/pr....oducts/remdesivir.ht
The analysis showed that an intermediate or therapeutic dose of anticoagulation did not decrease the prevalence of thrombotic events. On the other hand, six patients reported severe hemorrhagic complications. Despite intermediate or therapeutic-dose of anticoagulation, a high number of patients with acute respiratory failure secondary to COVID-19 developed thrombotic complications.The field of nanoinformatics is rapidly developing and provides data driven solutions in the area of nanomaterials (NM) safety. #link# Safe by Design appro
Like
Comment
Share